

Consequences of Exchanging Carbohydrates for Proteins in the Cholesterol Metabolism of Mice Fed a High-fat Diet

Frédéric Raymond^{1,9a}, Long Wang^{2,9}, Mireille Moser¹, Sylviane Metairon^{1a}, Robert Mansourian¹, Marie-Camille Zwahlen¹, Martin Kussmann^{3,4,5}, Andreas Fuerholz¹, Katherine Macé⁶, Chieh Jason Chou^{6*,a,b}

1 Bioanalytical Science Department, Nestlé Research Center, Lausanne, Switzerland, **2** Department of Nutrition Science and Dietetics, Syracuse University, Syracuse, New York, United States of America, **3** Proteomics and Metabonomics Core, Nestlé Institute of Health Sciences, Lausanne, Switzerland, **4** Faculty of Science, Aarhus University, Aarhus, Denmark, **5** Faculty of Life Sciences, Federal Institute of Technology, Lausanne, Switzerland, **6** Nutrition and Health Department, Nestlé Research Center, Lausanne, Switzerland

Abstract

Consumption of low-carbohydrate, high-protein, high-fat diets lead to rapid weight loss but the cardioprotective effects of these diets have been questioned. We examined the impact of high-protein and high-fat diets on cholesterol metabolism by comparing the plasma cholesterol and the expression of cholesterol biosynthesis genes in the liver of mice fed a high-fat (HF) diet that has a high (H) or a low (L) protein-to-carbohydrate (P/C) ratio. H-P/C-HF feeding, compared with L-P/C-HF feeding, decreased plasma total cholesterol and increased HDL cholesterol concentrations at 4-wk. Interestingly, the expression of genes involved in hepatic steroid biosynthesis responded to an increased dietary P/C ratio by first down-regulation (2-d) followed by later up-regulation at 4-wk, and the temporal gene expression patterns were connected to the putative activity of SREBF1 and 2. In contrast, *Cyp7a1*, the gene responsible for the conversion of cholesterol to bile acids, was consistently up-regulated in the H-P/C-HF liver regardless of feeding duration. Over expression of *Cyp7a1* after 2-d and 4-wk H-P/C-HF feeding was connected to two unique sets of transcription regulators. At both time points, up-regulation of the *Cyp7a1* gene could be explained by enhanced activations and reduced suppressions of multiple transcription regulators. In conclusion, we demonstrated that the hypocholesterolemic effect of H-P/C-HF feeding coincided with orchestrated changes of gene expressions in lipid metabolic pathways in the liver of mice. Based on these results, we hypothesize that the cholesterol lowering effect of high-protein feeding is associated with enhanced bile acid production but clinical validation is warranted. (246 words)

Citation: Raymond F, Wang L, Moser M, Metairon S, Mansourian R, et al. (2012) Consequences of Exchanging Carbohydrates for Proteins in the Cholesterol Metabolism of Mice Fed a High-fat Diet. PLoS ONE 7(11): e49058. doi:10.1371/journal.pone.0049058

Editor: Stephane Blanc, Institut Pluridisciplinaire Hubert Curien, France

Received: November 21, 2011; **Accepted:** October 9, 2012; **Published:** November 6, 2012

Copyright: © 2012 Raymond et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: No current external funding sources for this study.

Competing Interests: All authors, except Dr. Long Wang, were employees of Nestec S.A. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

* E-mail: chieh-jason.chou@rd.nestle.com

9 These authors contributed equally to this work.

a Current address: Functional Genomics Core, Nestlé Institute of Health Sciences, Lausanne, Switzerland

b Current address: Gastrointestinal Health Department, Nestlé Institute of Health Sciences, Lausanne, Switzerland

Introduction

Obesity is one of the most frequently studied non-communicable diseases and excessive energy intake, reduced energy expenditure or combinations of both are related to its cause. Obesity is also associated with co-morbidities such as cardiovascular diseases, type 2 diabetes, sleep apnea, arthritis and cancers; the remission of many of which have been reported in patients after Roux-en-Y gastric bypass in morbidly obese subjects [1]. Consequently, the reduction of obesity-related morbidities is as important as the success of weight loss.

Recently, a number of clinical studies have reported rapid weight loss in obese subjects consuming low-carbohydrate diets [2,3,4,5,6,7,8,9,10]. Although the macronutrient compositions of the low-carbohydrate diets were different in each study, a proportional increase in proteins and fats was commonly found

in these diets [2,5,7]. However, the amount of fats, especially saturated fats, in the low-carbohydrate diets promoted concerns about the risk of developing cardiovascular disease. In contrast to this belief, recent studies have demonstrated improved cholesterol profiles with HDL cholesterol concentrations being either higher or less reduced, and triglyceride concentrations being lower in obese subjects after consuming low-carbohydrate, high-fat, high-protein diets than after consuming high-carbohydrate, low-fat diets [5,10]. However, the increase in LDL cholesterol, in spite of the concurrent elevation of HDL cholesterol, challenges the overall cardioprotective effect of low-carbohydrate high-fat diets [4].

In addition to increasing dietary fats, replacement of carbohydrates by proteins is another common feature of low-carbohydrate diets. Proteins have independent effects on plasma cholesterol concentrations. In humans, replacement of carbohydrates by

Table 1. Body weight gain and energy intake of mice fed different high-fat diets.

| | <i>Before treatment</i> | | <i>2-d after treatment</i> | | <i>4-wk after treatment</i> | | |
|----------|-------------------------|---------------|----------------------------|------------------|-----------------------------|--------------------|------------------|
| | BW (g) | BW (g) | BW gain (g) | EI (kcal) | BW (g) | BW gain (g) | EI (kcal) |
| L-P/C-HF | 34.2±1.2 | 35.0±1.1 | 0.75±0.10 | 25.5±0.8 | 37.8±1.2 | 3.63±0.43 | 249.3±3.8 |
| H-P/C-HF | 35.7±1.2 | 35.7±1.2 | 0.01±0.11* | 21.4±0.7* | 37.7±1.3 | 1.98±0.38* | 239.1±5.1 |

Data are mean ± sem, n = 12/group.

*p < 0.05 vs. L-P/C-HF group. BW, body weight. EI, energy intake.

doi:10.1371/journal.pone.0049058.t001

proteins in fat-restricted diets resulted in rapid weight loss, reduction of plasma triglyceride and elevation of HDL cholesterol concentrations [11]. In rodents, a high-casein, high-fat diet compared with a low-casein, high-fat diet increased circulating HDL cholesterol [12]. Endo et al. reported that 11 hepatic genes involved in cholesterol metabolism were down-regulated in rats fed a protein-free diet when compared with rats fed a 12% casein diet [13]. In the same study, it was also found that a gluten diet unilaterally increased 15 cholesterol biosynthesis genes when compared with a diet containing casein [13]. In addition to gluten, soy proteins have also been demonstrated to have cholesterol-lowering benefits. Concurrent up-regulation of genes involved in steroid metabolism and reduction of serum cholesterol by soy proteins suggests a well-coordinated transcriptional regulation. Over-abundance of sterol regulatory element-binding protein 2 (SREBP2) [14] and up-regulation of 3-hydroxy-3-methylglutaryl-coenzyme reductase (HMGCR), a SREBP2 target gene and the rate-limiting enzyme for cholesterol biosynthesis [15], were reported in rodents fed a soy protein diet. Thus, available evidence indicates that both the quantity and the quality of dietary proteins can regulate the expression of genes involved in hepatic cholesterol biosynthesis. However, it has not been shown how the amount of protein in the context of high-fat and low-carbohydrate diets would affect the expression of hepatic cholesterol biosynthesis genes. Understanding the metabolic adaptations to a high-fat, high-protein diet in the liver can reveal insights for assessing the cardioprotective effects of such a diet.

In the present study, we evaluated the effect of a high-protein and high-fat diet on cholesterol metabolism by examining plasma cholesterol concentrations and the expression of cholesterol biosynthesis genes in the liver of mice fed a high-fat (HF) diet that had either a high (H) or low (L) protein-to-carbohydrate ratio (P/C). Many organs can synthesize cholesterol but the liver is the principal site for cholesterol biosynthesis, which makes it a prime target for regulating cholesterol homeostasis [16]. In addition, we measured body weight, food intake and other circulating lipids at 2 days and at 4 weeks after introduction of the dietary treatments. We expected that the changes in macronutrient composition would have a broad impact on gene expression in multiple metabolic pathways in the liver, and selected microarray analyses to monitor global gene expression to reveal metabolic adaptations of the liver to the two different high-fat diets.

Results

Effects of P/C ratio in a HF diet on body weight and energy intake

Forty-eight glucose intolerant diet-induced obese (DIO) mice were randomized to receive either a background L-P/C-HF diet or an experimental H-P/C-HF diet. Although it was statistically insignificant, the initial weights of mice prior to the dietary

intervention were higher in the H-P/C-HF than in the L-P/C-HF group (Table 1). During the first 2 days of dietary intervention, H-P/C-HF mice consumed less calories and gained less weight than L-P/C-HF mice (Table 1). However, at sacrifice, body weight, liver, epididymal fat pad and gastrocnemius muscle weights were similar in both groups (Table 1 and S1). The suppressive effect of H-P/C-HF feeding on body weight gains was also observed after the 4-wk dietary treatment, and the weight gains were significantly less in the H-P/C-HF mice than in L-P/C-HF mice (Table 1). Energy intake was also lower in H-P/C-HF mice than L-P/C-HF mice, but the difference did not reach statistical significance (Table 1). Body weight, liver, epididymal fat pad, brown fat pad and gastrocnemius muscle weights were indistinguishable between the two groups at the end of the 4-wk treatment period (Table S1).

Effects of exchanging carbohydrate for protein on whole body glucose tolerance

To assess whether the ratio of dietary protein to carbohydrate affects insulin sensitivity of DIO mice, an intraperitoneal glucose tolerance test (IPGTT) was performed after the 4-wk dietary treatment. As indicated in Table 2, H-P/C-HF feeding did not affect the peak glucose value or the area under the glucose curve during the IPGTT. Baseline insulin and peak insulin levels were also comparable in the two groups (Table 2). The overnight fasting blood glucose level was the only parameter which showed a trend to be lower in H-P/C-HF than in L-P/C-HF mice (Table 2).

The Diet high in P/C ratio partially improved dyslipidemia in DIO mice

The plasma lipid profiles of mice fed two different HF diets were compared. After 2-d H-P/C-HF feeding, plasma triglyceride (TG) (Fig. 1A) and plasma free fatty acid (FFA) concentrations (Fig. 1B) were reduced, whereas total cholesterol (Fig. 1C) and plasma HDL cholesterol concentrations were unchanged (Fig. 1D). After 4-wk HF feeding, plasma TG and FFA concentrations increased regardless of the dietary P/C ratio (Fig. 1A and 1B). In contrast, plasma total cholesterol was lower in H-P/C-HF mice than in L-P/C-HF mice (Fig. 1C). Extending the L-P/C-HF feeding significantly increased plasma total cholesterol (from 127.01±7.17 mg/dL after 2-d to 163.96±10.60 mg/dL after 4-wk, p = 0.002), but this trend was not observed in H-P/C-HF mice (p = 0.28, Fig. 1C). Plasma HDL cholesterol displayed a different temporal pattern in response to H-P/C-HF feeding. At 2-d, the diet change had no effect on HDL cholesterol but 4-wk H-P/C-HF feeding significantly increased HDL cholesterol when compared with L-P/C-HF feeding (Fig. 1D). As a consequence, the plasma HDL cholesterol to total cholesterol ratio (HDL/total Chol) was markedly affected by both the dietary P/C ratio and feeding duration. In the L-P/C-HF group, the HDL/total Chol ratio was reduced from 53.2±4.4% after 2-d to 44.5±2.3% after 4-wk of feeding (p = 0.003), whereas the HDL/total Chol ratio in

Table 2. Results of intraperitoneal glucose tolerance test (IPGTT) in mice fed the L-P/C-HF or H-P/C-HF diet for 4-wk.

| | Baseline glucose (mg/dL) | Peak glucose (mg/dL) | Glucose AUC (mg/dL*min) | Baseline insulin (ng/mL) | Peak insulin (ng/mL) |
|----------|--------------------------|----------------------|-------------------------|--------------------------|----------------------|
| L-P/C-HF | 104.5±11.3 | 463±24.4 | 31807±1577 | 0.72±0.16 | 1.19±0.22 |
| H-P/C-HF | 92.5±5.6 [§] | 464±27.5 | 29302±2047 | 0.59±0.14 | 0.95±0.13 |

Data are median ± semedian, n=12/group.

[§]0.1>p>0.05. Peak blood glucose and peak plasma insulin levels were determined at 15 minutes after the glucose challenge.

doi:10.1371/journal.pone.0049058.t002

the H-P/C-HF fed mice remained similar (54.7±3.5% at 2-d vs. 63.8±5.1% at 4-wk, $p=0.178$). At the end of the 4-wk study, the difference in HDL/tot Chol between the two groups was statistically significant (63.8±5.1% in H-P/C-HF group vs. 44.5±2.3% in L-P/C-HF group $p<0.001$). In contrast to plasma cholesterol, the liver total cholesterol concentration was not affected by the dietary P/C ratio nor by the duration of the treatment (Fig. 2A). Prolonged L-P/C-HF feeding caused accumulation of liver TG, which was prevented by H-P/C-HF feeding (Fig. 2B).

Temporal responses of hepatic steroid metabolism genes to H-P/C-HF feeding

To investigate if the liver was involved in the changes of plasma cholesterol levels after H-P/C-HF feeding, we performed a global gene expression analysis using Affymetrix GeneChips. Two days

after the diet switch, 412 transcripts ($p<0.001$) were found to be differentially expressed between the H-P/C-HF and L-P/C-HF groups (Table S2). Pathway analysis of the differentially expressed genes showed that the biosynthesis of steroids pathway was the most significant differentially regulated canonical pathway in the liver of H-P/C-HF mice (Table 3) where all of the differentially regulated genes in the steroid biosynthesis pathway were down-regulated (Fig. 3A). To find out which transcription factor might be responsible for the down-regulation of steroid biosynthesis genes, we performed upstream regulator analysis with the entire dataset. Globally, AHR and NR1H3 were predicted “active” and SREBF2, SREBF1 and CEBPB were predicted “inhibit” (Table S3). Semantic relationship analysis showed that *Sqle* (−1.73), *Fdps* (−1.63), *Fdft1* (−1.28), *Mod* (−1.22), *Lss* (−1.22), *Sc5d* (−1.34), and *Idi1* (−1.58) were direct targets of SREBF1 and 2 (Fig. 3A). In addition, the expression of *Srebf2* was significantly reduced (−1.24)




Figure 1. Amelioration of dyslipidemia by H-P/C-HF feeding. Plasma triglyceride (TG) (A), free fatty acids (FFA) (B), total cholesterol (C) and HDL cholesterol (D) concentrations in mice consuming the L-P/C-HF or the H-P/C-HF diet for 2-d and 4-wk. Data are median ± semedian, n=12/group except for H-P/C-HF 2-d, n=11. * $p<0.05$ by Wilcoxon test. doi:10.1371/journal.pone.0049058.g001




Figure 2. Accumulation of lipids in the liver of mice fed the L-P/C-HF or the H-P/C-HF diet. Total cholesterol (A) and triglycerides (TG) (B) in the liver of mice fed two different high-fat diets for 2-d and 4-wk. Data are median \pm semedian, n = 12/group except for H-P/C-HF 2-d, n = 11. * p < 0.05 by Wilcoxon test. doi:10.1371/journal.pone.0049058.g002

in the H-P/C-HF liver, further suggesting the important role of SREBF2 in down-regulation of steroid biosynthesis genes.

At 4-wk, 330 transcripts were differentially regulated (p < 0.001) between the two diet groups (Table S4) and the biosynthesis of steroids pathway was still one of the most differentially regulated canonical pathways in the H-P/C-HF liver (Table 4). In contrast with the 2-d results, all differentially regulated steroid biosynthesis genes (*Hmgcr*, *Idi1*, *Fdps*, *Sqle*, *Dhcr7* and *Pmk1*), including *Hmgcr* - that is the gene encoding the rate limiting enzyme for cholesterol biosynthesis - were up-regulated at 4-wk. Upstream regulator analysis indicated that SREBF2, SREBF1, SIRT2, FOXO1, EGR2, PPARGC1B were predicted “active”, whereas PPARA, CEBPE, HMGA1 and WT1 were predicted “inhibit” (Table S5). Putative transcriptional activities of SREBF1 and 2 coincided with

the up-regulation of many steroid biosynthesis genes, which suggests the functional importance of both transcription factors in mediating the changes of steroid biosynthesis after H-P/C-HF feeding.

Persistent up-regulation of *Cyp7a1* by H-P/C-HF feeding

In contrast to the temporal expression pattern of steroid biosynthesis genes, *Cyp7a1* expression was persistently up-regulated in the H-P/C-HF liver regardless of the duration of feeding (Fig. 4A and 4B). *Cyp7a1* belongs to the Cyp450 family and its function is to add a hydroxyl moiety to the 7 α position of cholesterol. This enzymatic activity is the rate limiting step for converting cholesterol to bile acids and is important for cholesterol homeostasis [17]. In the liver, the expression of *Cyp7a1* is




Figure 3. Effect of H-P/C-HF feeding on the expression of selected SREBF1 and 2 target genes. Upstream regulator analyses were performed using all of the differentially regulated genes between the two diet groups; only SREBF1 and 2 showed relevant connections to the steroid biosynthesis genes. Differentially regulated SREBF1 and 2 target genes at either time point were selected for building a relationship network, Down-regulated genes after 2-d H-P/C-HF feeding are shown in (A), and up-regulated genes after 4-wk H-P/C-HF feeding are shown in (B). Genes and the steroid biosynthesis pathway are represented as nodes. The red and green colors indicate up- and down-regulation in the H-P/C-HF compared with the L-P/C-HF group, respectively. Fold change of differentially regulated genes is indicated by the number below the gene name. Red and green lines connecting from SREBF1 and 2 to different nodes indicate positive and negative contributions, respectively. Red and green border colors of SREBF1 and 2 indicate the putative transcription activity as “active” and “inhibit”, respectively. The image was created using Ingenuity Pathways Analysis software. doi:10.1371/journal.pone.0049058.g003

Table 3. Top 5 differentially regulated canonical pathways between H-P/C-HF and L-P/C-HF feeding for 2-d.

| Inguenity Canonical Pathways | −log(p-value) | Molecules |
|--|---------------|---|
| Biosynthesis of Steroids | 6.86E00 | MVD,FDPS,SQLC,FDFT1,IDI1,LSS,SC5DL |
| Alanine and Aspartate Metabolism | 5.05E00 | ASS1, GPT, CRAT, GOT1, ASNS, AGXT, ASL |
| Fatty Acid Metabolism | 4.72E00 | ALDH1B1, Cyp2b13/Cyp2b9, ACSL3, ACADL, Cyp4a14, CYP2A6 (includes others), CYP1A2, ACOX1, CYP2B6, SDS, CYP51A1, CYP1B1 |
| LPS/IL-1 Mediated Inhibition of RXR Function | 4.52E00 | ALDH1B1, ACSL3, FMO2, ACOX1, GSTA5, SLC01A2, GSTT2/GSTT2B, Cyp4a14, CYP2A6 (includes others), FABP5, SULT1A1, CYP7A1, FABP4, CYP2B6, HMGCS1 |
| Tryptophan Metabolism | 4.4E00 | AFMID, ALDH1B1, Cyp2b13/Cyp2b9, CYP2A6 (includes others), CYP1A2, CYP2B6, INMT, SDS, CYP51A1, KYNU, CYP1B1 |

doi:10.1371/journal.pone.0049058.t003

transcriptionally regulated by many factors including FOXO1 [18], LRH-1 [19], LXR α [20], HNF-4 α [21], Onecut1 (HNF-6) [22], NROB2 [23,24] and others. However, the responsible transcription regulator(s) that mediate the expression of *Cyp7a1* in the present study were not clear. To answer the question, we selected the transcription regulators that had a statistically significant relationship ($p < 0.05$) with *Cyp7a1* gene expression from semantic relationship analyses. The transcription regulators that are known to activate or inhibit *Cyp7a1* gene expression were placed above or below *Cyp7a1*, respectively. Then, the activity of each transcription regulator was predicted according to upstream regulator analysis and the outcomes were overlaid on the existing relationships with *Cyp7a1*. Illustrated in Fig. 4A, NR1I3 (LXR α) and SREBF1 were predicted to control *Cyp7a1* gene expression after 2-d H-P/C-HF feeding, and the state of NR1I3 and SREBF1 was predicted as “active” and “inhibit” according to upstream regulator analysis, respectively. Because NR1I3 is known to positively induce *Cyp7a1* gene expression, whereas SREBF1c is known to negatively regulate it [20,25], up-regulation of *Cyp7a1* can be explained by a direct activation by NR1I3 and reduced inhibition by SREBF1. After 4-wk of H-P/C-HF feeding, FOXO1, Onecut1, NR1I2, NR0B2 and PROX1 were predicted to have a functional relationship with *Cyp7a1* gene expression. Positive regulators including FOXO1 and Onecut1 were predicted to be active and Onecut1 mRNA expression was up-regulated in the H-P/C-HF liver. The state of negative regulators, NR1I2 (PXR), NR0B2 (SHP) and PROX1 were predicted as “inhibit”. Altogether, bioinformatic analyses indicated that up-regulation of *Cyp7a1* gene expression after 4-wk H-P/C-HF feeding is connected to the enhanced transcriptional activation by FOXO1 and Onecut1 and the reduced transcriptional suppression by NR1I2, NR0B2 and PROX1.

Discussion

In the present study, we investigated the effect of the protein-to-carbohydrate ratio of HF diets on cholesterol metabolism, body weight and glucose tolerance in mice. Our results agree with much of the literature demonstrating that higher amounts of dietary protein suppresses body weight gain [26,27,28,29]. Also in agreement with data by Ratnayake et al. [12], our results showed that 4-wk of H-P/C-HF feeding resulted in lower plasma total cholesterol and increased HDL cholesterol. Novel findings of the present study are two folds. First, in response to the increased dietary protein-to-carbohydrate ratio, genes in the steroid biosynthesis pathway displayed complex time-dependent bi-directional expression patterns with an initial down-regulation followed by a later up-regulation. Predicted transcriptional activity of SREBF1 and 2 coincided with the expression levels of all differentially expressed steroid biosynthesis genes. Second, hepatic *Cyp7a1* gene expression was persistently up-regulated regardless of the duration of H-P/C-HF feeding, but two unique sets of transcription regulators were connected to the expression of *Cyp7a1* at 2-d and 4-wk of H-P/C-HF feeding. Through the combination of physiological measurements and bioinformatic analyses of global gene expression data, our results indicate that both hepatic steroid and bile acid metabolic pathways were physiological targets of high-protein feeding. Moreover, the increased bile acid production is a novel hypothesis that should be further studied when assessing the risk of negative cardiovascular outcomes with long-term consumption of high-protein, high-fat diets.

Effect of exchanging carbohydrate for protein on cholesterol homeostasis

One of the novel and unexpected findings of the present study is the biphasic expression pattern of steroid biosynthesis genes during

Table 4. Top 5 differentially regulated canonical pathways between H-P/C-HF and L-P/C-HF feeding for 4-wk.

| Inguenity Canonical Pathways | −log(p-value) | Molecules |
|--|---------------|--|
| Biosynthesis of Steroids | 5.88E00 | FDPS, SQLC, DHCR7, PMVK, IDI1, HMGCR |
| Complement System | 5.11E00 | CFD, MBL2, C1QC, C1QA, C1QB, C3AR1 |
| Glycine, Serine and Threonine Metabolism | 4.52E00 | SRR, GNMT, ELOVL2, ALAS1, GOT1, GNA14, CTH, AGXT |
| LPS/IL-1 Mediated Inhibition of RXR Function | 3.95E00 | ALDH1B1, ABCG5, Cyp4a14, NR0B2, NR1I2, ACOX1, GSTA5, CYP7A1, CD14, ALAS1, FMO5, ACSL1 |
| Fatty Acid Metabolism | 3.79E00 | ALDH1B1, CYP3A43, CYP1A1 (includes EG:13076), Cyp4a14, CYP4A22, ACOX1, Cyp2c70, ACSL1, CYP51A1 |

doi:10.1371/journal.pone.0049058.t004

expression of cholesterol biosynthesis genes [32]. However, the target genes of both transcription factors are not mutually exclusive as SREBF1 and SREBF2 have been reported to regulate the expression of cholesterol and fatty acid biosynthesis genes [33,34]. The lack of specificity of these transcription factors to steroid biosynthesis genes can explain why both SREBF1 and 2 were predicted to mediate the changes in the expression of steroid biosynthesis genes in the present study.

SREBF2-dependent cholesterol biosynthesis is controlled by complex cellular regulation, and cholesterol binding to regulatory proteins and posttranslational modifications of SREBF2 are two important steps which are required to activate SREBF2 [35]. Upon the demand of *de novo* cholesterol synthesis, inactive SREBF2 anchoring at the endoplasmic reticulum (ER) has to be processed and translocated to the nucleus to activate the transcription of target genes [36,37]. One of the key steps governing the activation of SREBF2 is the cholesterol concentration of ER membranes. When ER cholesterol level falls below 5% of total polar lipids, the SREBF complex escorted by the SREBP cleavage-activating protein, SCAP, is transported from the ER to the Golgi apparatus [38], a key commitment step for activating SREBF2. In the present study, coordinated SREBF2 transcriptional activities and the time-dependent biphasic expression of steroid biosynthesis genes suggest that the cholesterol concentration of the ER is modified by the increased dietary protein-to-carbohydrate ratio. However, the ER cholesterol concentration was not determined and future studies are needed to validate this hypothesis.

In addition to *de novo* cholesterol biosynthesis, the balance of cellular cholesterol is regulated by uptake and export mechanisms in cells. Conversion of cholesterol to bile acids is one of the major routes for reducing cellular cholesterol concentrations and is critical for excreting cholesterol from the body [39]. Thus, the activity of *Cyp7a1* that controls the rate-limiting step of bile acid biosynthesis using cholesterol as a substrate is important for maintaining whole body cholesterol homeostasis. This argument is supported by the fact that overexpression of *Cyp7a1* in mice resulted in elevated bile acid production and simultaneous reductions of plasma VLDL, IDL and LDL cholesterol and elevations in plasma HDL cholesterol [40]. In the present study, persistent up-regulation of *Cyp7a1* following H-P/C-HF feeding increased the bile acid concentration and simultaneously depleted cellular cholesterol which in the long-term could trigger the SREBF2-dependent up-regulation of cholesterol biosynthesis genes. Recently, Bortolotti et al. showed that the consumption of a high-protein, high-fat diet coincided with significant increases in circulating bile acids in humans [41], an observation that is relevant to the results of our transcriptomic analyses.

Physiological impact of a high P/C ratio diet on body weight and glucose tolerance in mice

H-P/C-HF feeding significantly reduced body weight gains, but body weights at sacrifice were similar in both diet groups. The lack of difference in body weights is likely due to the following reasons. First, mice assigned to H-P/C-HF group were slightly heavier than control mice before feeding started. Second, the feeding duration was too short to demonstrate the effect of increasing dietary protein. In a study in which mice were fed experimental diets for 70 days, both body weight and weight gains were greater in mice fed a high-carbohydrate, high-fat diet than mice fed a low-carbohydrate, high-fat diet [42]. Third, high-protein feeding increases muscle protein synthesis [43], which may offset the weight loss effect of a high-protein diet. A future study aiming to

measure the body composition of the mice after the high-protein diet feeding will be needed to confirm this hypothesis.

Recently, the effects of dietary protein on insulin sensitivity have been evaluated. In contrast to the anti-obesity effect, it remains controversial whether a high-protein diet improves insulin sensitivity. On one hand, feeding a high-protein diet for 6 months or longer induces insulin resistance in healthy non-obese individuals [44] and rats [45] leading to the argument that high-protein intake causes detrimental effects on glucose homeostasis by increasing insulin resistance [46], while on the other, eating a high-fat, high-protein diet for 5 weeks reduced plasma glucose, insulin, glucagon and triglyceride concentrations in weight stable type 2 diabetic patients [47]. The latter study is especially important because the experimental diet was high in fat and protein, and the data suggest that the levels of protein in such a diet can overcome the pathogenic nature of dietary fat and reverse insulin resistance.

In the present study, basal and peak insulin concentrations as well as plasma glucose clearance during the IPGTT were comparable in both groups, which indicate that the P/C ratio had little or no effect on glucose-stimulated insulin secretion and insulin-stimulated glucose uptake in skeletal muscle and adipose tissue under our experimental conditions. The only parameter that showed a trend to be lower after 4-wk H-P/C-HF feeding was fasting glycemia. The reduced fasting glycemia was associated with down-regulation of hepatic glucose 6 phosphatase catalytic subunit (*G6pc*) (-1.266) in the H-P/C-HF liver compared with the L-P/C-HF liver. G6PC catalyzes the dephosphorylation of glucose-6-phosphate and is the final step in glycogenolysis and *de novo* gluconeogenesis before releasing glucose into the circulation. Although increased hepatic gluconeogenesis can be independent of *G6pc* expression [48], a high level of *G6pc* expression is found in the liver of streptozotocin-treated diabetic rats [49]. Reduced *G6pc* expression could indicate reduced hepatic glucose output. Another important step which regulates gluconeogenesis is phosphoenolpyruvate carboxykinase (PCK1), however, *Pck1* in the liver was not differentially regulated by the diets in the present study. Hepatic steatosis is another marker that reflects liver insulin sensitivity. The amount of fat stored in the liver was significantly lower in H-P/C-HF mice than in L-P/C-HF mice. Together, our data suggest that increasing the dietary P/C ratio moderately enhances hepatic insulin sensitivity without affecting skeletal and adipose tissue insulin sensitivity, and this hypothesis should be validated using the hyperinsulinemic euglycemic clamp in a future study.

In summary, we tested whether a high-fat, high-protein diet has any effect on cholesterol metabolism. Our data demonstrate that replacement of carbohydrate by protein suppressed high-fat diet-induced hypercholesterolemia, weight gain and hepatic steatosis. By using microarray analyses, we showed that the dietary P/C ratio had time-dependent biphasic effects on the expression of steroid biosynthesis genes that are connected to the activity of SREBF1 and 2. We also identified that a high P/C ratio in a high-fat diet increased *Cyp7a1* expression and this effect was possibly orchestrated by two unique sets of transcription regulators at the acute and chronic feeding phases. More importantly, our data suggest that the cholesterol lowering effect of high-protein diets is due to enhanced bile acid production, a hypothesis that is relevant to assess the cardiovascular outcomes of high-protein high-fat feeding and should be confirmed in a long-term human study.

Materials and Methods

Animal experiment

The ethics of the study protocol was reviewed and approved by the Nestlé Research Center Animal Studies Committee (No. JC-05-01) and the experiments were conducted under authorization No. 1837 issued by the Service de la Consommation et des Affaires Vétérinaires (SCAV), Vaudois, Switzerland. Sixty-eight male C57BL/6J mice aged 6–7 weeks were obtained from Charles River Laboratories. They were housed individually in a room with a 12-h light-dark cycle with food (3434 Kliba AG, Kaiseraugst, Switzerland) and water *ad libitum* for 2-wk.

To induce diet-induced obesity (DIO), mice were given free access to water and a low-protein to carbohydrate ratio, high-fat diet (L-P/C-HF) with 55% energy from fat, 30% from carbohydrate, and 15% from protein (Table S6) for 10-wk. On Days 70 and 71, an intraperitoneal glucose tolerance test (IPGTT) was performed after 6-hr fasting starting at 08:00. A 30% glucose solution was injected into the intraperitoneal cavity at a dose of 2 g/kg body weight. Blood samples were collected from the tail vein at 0, 30, 60, and 90 minutes after the glucose injection. Blood glucose was determined by using an Ascensia Elite XL glucometer (Bayer AG, Zurich, Switzerland) in duplicate. Based on the results, forty-eight mice with the highest area under the glucose curve were selected for the diet intervention study on Day 72. Selected DIO mice were randomized into two groups ($n = 24/\text{group}$). One group of DIO mice was fed a high protein to carbohydrate ratio high-fat diet (H-P/C-HF) with 55% energy from fat, 15% from carbohydrate, and 30% from protein (Table S6). The other group of DIO mice continued eating the same L-P/C-HF diet. Twelve mice in each group were sacrificed on Day 74 (2-d feeding) and the remaining 12 mice were euthanized on Days 100 or 101 (4-wk feeding). During the diet study, body weight and food intake were monitored daily except for the weekends. On Days 93 & 94, an IPGTT was performed after a 15-hr overnight fast. The following morning, a 30% glucose solution was injected into the intraperitoneal cavity at a dose of 2 g/kg body weight. Blood samples were collected from the tail vein at 0, 15, 30, 60, and 120 minutes after glucose injection to determine glucose concentrations using the aforementioned method. Blood samples at 0, 15, and 120 minutes were also collected from the tail vein for insulin analysis. Plasma insulin concentrations were determined by Ultra Sensitive Rat Insulin ELISA Kits with mouse insulin standard (Crystal Chem Inc., Downers Grove, IL, USA) following instructions from the manufacturer. Mice were anesthetized by isoflurane (Aerrane, Baxter, Maurepas, France) before sacrifice, after which the liver, epididymal fat pads, gastrocnemius muscle, colon, and gut contents were collected and snap frozen in liquid nitrogen. Blood samples were collected in EDTA-coated tubes.

Plasma and liver parameters

Plasma free fatty acids (FFA) were determined by an enzymatic colorimetric test using Wako NEFA C Kit (Wako Chemicals GmbH, Neuss, Germany) following the instructions provided by the manufacturer. Plasma triglycerides (TG) were determined using Triglycéride Enzymatique PAP 150 Kits (BioMérieux SA, Marcy-l'Etoile, France). Plasma total cholesterol and HDL cholesterol were measured by Wako total cholesterol and by Wako HDL cholesterol (Wako Chemicals GmbH, Neuss, Germany) kits, respectively. For determination of liver triglyceride and cholesterol concentrations, lipids in 200 mg frozen liver were extracted according to Folch et al. [50]. Liver total cholesterol (Roche diagnostics; Basel, Switzerland) and triglyceride (Roche Diagnostics; Basel; Switzerland) concentrations were quantified

using commercial enzymatic colorimetric kits. For the triglyceride measurements, lipids were first hydrolyzed in a basic solution of 0.5N KOH in ethanol.

Statistical analysis

Due to the presence of outliers, 2-ways ANOVA with interaction on the rank of the data was performed, and Wilcoxon tests were performed to assess the effect of diet and treatment duration. All data were presented as median \pm semedian except for Table 1 where data were presented as mean \pm sem. The semedian was computed based on the robust standard deviation: Sn of Rousseeuw. Analysis was performed with R 2.6.1: R Development Core Team (R Foundation for Statistical Computing, Vienna, Austria 2007. ISBN 3-900051-07-0, URL <http://www.R-project.org>).

Microarray analysis

RNA extraction, sample preparation and chip processing. Liver total RNA was extracted from frozen tissue using TriPure Isolation Reagent (Roche Applied Science, Indianapolis, IN, USA), following the manufacturer's instructions. RNA samples were then purified by NucleoSpin RNA II kit (Macherey-Nagel AG, Oensingen) following the manufacturer's instructions. The quality of RNA samples was checked by using the RINA 6000 Nano Assay on the Agilent 2100 BioAnalyzer (Agilent Technologies, Inc., Palo Alto, CA, USA). Only samples with a RNA integrity number (RIN) higher than 7.5 were used for microarray analysis. For samples that did not meet the requirement, extraction and purification were repeated. Total RNA samples were stored at -80°C before microarray analysis.

All cRNA targets were synthesized, labeled, and purified according to the Affymetrix protocol. This method is based on the Eberwine T7 procedure [51]. Briefly, 5 μg of liver total RNA were used to produce double-stranded cDNA, followed by *in vitro* transcription, and cRNA labelling with biotin before hybridizing to the Affymetrix GeneChip mouse genome 430 2.0 chips (CA, USA), and the results were scanned by an Affymetrix GeneChip scanner 3000 7G.

Microarray data processing and statistical analysis. Data were normalized using the Robust Multichip Average (RMA) method. Based on the normal distribution of the datasets, the parametric Pearson's product moment correlation was applied for quality control (Figure S1A). The data matrix was further clustered in order to identify groups of potential outliers (Figure S1B). To validate the quality of datasets, a principle component analysis (PCA) followed by a leave-one-out cross-validation was applied (Figure S2, Table S7 and S8). Based on the quality test of microarray datasets, B25 was identified as an outlier, and the data was subsequently removed from the final analysis.

One-way Analysis of Variance (ANOVA) followed by Global Error Assessment (GEA) [52] was applied to discriminate the difference of hepatic gene expressions between H-P/C-HF and L-P/C-HF feeding for 2-d and 4-wk. The robust Mean Square Error (MSE) resulting from GEA was then used to calculate a new F-statistic and a robust p-value. The p-value was set at 0.001 for further analysis. The microarray data have been deposited in Gene Expression Omnibus, and the accession number is GSE20260 (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE20260>).

Ingenuity pathway analysis. Probes selected by the statistical analysis along with their differential expression value were loaded into Ingenuity Pathways Analysis software (IPA) (Ingenuity Systems, www.ingenuity.com) for annotation, redundancy checks and network and pathway analysis. The IPA Reference set was Affymetrix

Mouse_430 2, and Direct and Indirect relationships were selected for analyses. Then IPA computed the data with the satisfaction of the right-tailed Fisher's Exact Test and generated significant networks based on semantic associations of these genes in metabolic or cell-signaling pathways that have been shown in published articles, books, and KEGG Ligand. For the genes with multiple probesets on the microarray, only the averaged value of fold change is reported, and individual values are shown in Table S2 and S4.

Supporting Information

Figure S1 Quality control of Affymetrix chips. Intensity plot of Pearson's product correlation matrix.
(TIF)

Figure S2 Cluster analysis of the intensity plot, whereas B25, A24, A09, and A01 were grouped in two sub-clusters, separated from the other datasets, respectively.
(TIF)

Figure S3 Principal component analysis (PCA) and Leave-one-out (LOO) cross validation. The contributions to the overall variance are plotted for each putative outlier and for the first 5 components respectively.
(TIF)

Table S1 Organ weight of mice at sacrifice. Data are median \pm SE, n = 12/group. ND, not determined.
(DOC)

Table S2 List of regulated transcripts after H-P/C-HF feeding for 2 days. All differentially expressed transcripts ($p < 0.001$) resulting from a comparison of H-P/C-HF with L-P/C-HF mice after 2-d of feeding are listed. The significance of differences was estimated by a moderated ANOVA as described in the Material and Method section. The fold change with a negative and a positive value indicates down-regulation and up-regulation in the H-P/C-HF group, respectively. An Affymetrix probeset ID (Mouse 430 2.0) is provided for each gene. R in Notes represents a replicated detection with an alternative probeset for a given gene on the microarray.
(DOC)

Table S3 Transcription factor analysis of global gene expressions at 2-d after H-P/C-HF feeding.
(DOC)

References

- Rossi M, Serpa Neto A, Rossi FM, Amarante RD, Alcantara GC Jr, et al. (2009) Percentage of excess BMI lost correlates better with improvement of metabolic syndrome after Roux-en-Y gastric bypass in morbidly obese subjects: anthropometric indexes and gastric bypass. *Surg Obes Relat Dis* 5: 11–18.
- Brehm BJ, Seeley RJ, Daniels SR, D'Alessio DA (2003) A randomized trial comparing a very low carbohydrate diet and a calorie-restricted low fat diet on body weight and cardiovascular risk factors in healthy women. *J Clin Endocrinol Metab* 88: 1617–1623.
- Brehm BJ, Spang SE, Lattin BL, Seeley RJ, Daniels SR, et al. (2005) The role of energy expenditure in the differential weight loss in obese women on low-fat and low-carbohydrate diets. *J Clin Endocrinol Metab* 90: 1475–1482.
- Brinkworth GD, Noakes M, Buckley JD, Keogh JB, Clifton PM (2009) Long-term effects of a very-low-carbohydrate weight loss diet compared with an isocaloric low-fat diet after 12 mo. *Am J Clin Nutr* 90: 23–32.
- Foster GD, Wyatt HR, Hill JO, McGuckin BG, Brill C, et al. (2003) A randomized trial of a low-carbohydrate diet for obesity. *N Engl J Med* 348: 2082–2090.
- Gardner CD, Kiazand A, Alhassan S, Kim S, Stafford RS, et al. (2007) Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A TO Z Weight Loss Study: a randomized trial. *JAMA* 297: 969–977.
- Samaha FF, Iqbal N, Seshadri P, Chicano KL, Daily DA, et al. (2003) A low-carbohydrate as compared with a low-fat diet in severe obesity. *N Engl J Med* 348: 2074–2081.
- Seshadri P, Iqbal N, Stern L, Williams M, Chicano KL, et al. (2004) A randomized study comparing the effects of a low-carbohydrate diet and a conventional diet on lipoprotein subfractions and C-reactive protein levels in patients with severe obesity. *Am J Med* 117: 398–405.
- Shai I, Schwarzfuchs D, Henkin Y, Shahar DR, Witkow S, et al. (2008) Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. *N Engl J Med* 359: 229–241.
- Stern L, Iqbal N, Seshadri P, Chicano KL, Daily DA, et al. (2004) The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trial. *Ann Intern Med* 140: 778–785.
- Skov AR, Toubro S, Romm B, Holm L, Astrup A (1999) Randomized trial on protein vs carbohydrate in ad libitum fat reduced diet for the treatment of obesity. *Int J Obes Relat Metab Disord* 23: 528–536.
- Ratnayake WM, Sarwar G, Laffey P (1997) Influence of dietary protein and fat on serum lipids and metabolism of essential fatty acids in rats. *Br J Nutr* 78: 459–467.
- Endo Y, Fu Z, Abe K, Arai S, Kato H (2002) Dietary protein quantity and quality affect rat hepatic gene expression. *J Nutr* 132: 3632–3637.
- Torre-Villalvazo I, Tovar AR, Ramos-Barragan VE, Carbon-Cervantes MA, Torres N (2008) Soy protein ameliorates metabolic abnormalities in liver and adipose tissue of rats fed a high fat diet. *J Nutr* 138: 462–468.
- Ascencio C, Torres N, Isoard-Acosta F, Gomez-Perez EJ, Hernandez-Pando R, et al. (2004) Soy protein affects serum insulin and hepatic SREBP-1 mRNA and reduces fatty liver in rats. *J Nutr* 134: 522–529.

Table S4 List of regulated transcripts after H-P/C-HF feeding for 4 wks. All differentially expressed transcripts ($p < 0.001$) resulting from a comparison of H-P/C-HF with L-P/C-HF mice after 4-wk of feeding are listed. The significance of differences was estimated by a moderated ANOVA as described in the Material and Method section. The fold change with a negative and a positive value indicates down-regulation and up-regulation in the H-P/C-HF group, respectively. An Affymetrix probeset ID (Mouse 430 2.0) is provided for each gene. R in Notes represents a replicated detection with a different probeset for a given gene on the microarray.
(DOC)

Table S5 Transcription factor analysis of global gene expressions at 4-wk after H-P/C-HF feeding.
(DOC)

Table S6 Nutritional composition of the diets.
(DOC)

Table S7 Arrays were used to perform the LOO analysis for cross validation of the PCA.
(DOC)

Table S8 A one-way ANOVA was applied to identify the outlier which significantly reduced the overall variability. B25 reduced the variability down to 61.9% of the initial variance.
(DOC)

Text S1
(DOC)

Acknowledgments

Authors wish to thank Dr. Kevin Acheson for critical comments and editing and Corinne Ammon Zufferey, Irina Monnard for technical supports, and José-Luis Sanchez Garcia for animal husbandry.

In memory of our friend and colleague Dr. Andreas Fuerholz.

Author Contributions

Conceived and designed the experiments: CJC KM MK. Performed the experiments: LW SM. Analyzed the data: FR MM RM MCZ AF. Wrote the paper: CJC FR.

16. Charlton-Menys V, Durrington PN (2008) Human cholesterol metabolism and therapeutic molecules. *Exp Physiol* 93: 27–42.
17. Shin DJ, Campos JA, Gil G, Osborne TF (2003) PGC-1 α activates CYP7A1 and bile acid biosynthesis. *J Biol Chem* 278: 50047–50052.
18. Li T, Kong X, Owsley E, Ellis E, Strom S, et al. (2006) Insulin regulation of cholesterol 7 α -hydroxylase expression in human hepatocytes: roles of forkhead box O1 and sterol regulatory element-binding protein 1c. *J Biol Chem* 281: 28745–28754.
19. Nitta M, Ku S, Brown C, Okamoto AY, Shan B (1999) CPF: an orphan nuclear receptor that regulates liver-specific expression of the human cholesterol 7 α -hydroxylase gene. *Proc Natl Acad Sci USA* 96: 6660–6665.
20. Gupta S, Pandak WM, Hylemon PB (2002) LXR α is the dominant regulator of CYP7A1 transcription. *Biochem Biophys Res Commun* 293: 338–343.
21. Stroup D, Chiang JY (2000) HNF4 and COUP-TFII interact to modulate transcription of the cholesterol 7 α -hydroxylase gene (CYP7A1). *J Lipid Res* 41: 1–11.
22. Wang M, Tan Y, Costa RH, Holterman AX (2004) In vivo regulation of murine CYP7A1 by HNF-6: a novel mechanism for diminished CYP7A1 expression in biliary obstruction. *Hepatology* 40: 600–608.
23. Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, et al. (2000) A regulatory cascade of the nuclear receptors FXR, SHP-1, and LXR-1 represses bile acid biosynthesis. *Mol Cell* 6: 517–526.
24. Lu TT, Makishima M, Repa JJ, Schoonjans K, Kerr TA, et al. (2000) Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. *Mol Cell* 6: 507–515.
25. Kim HJ, Kim JY, Park SK, Seo JH, Kim JB, et al. (2004) Differential regulation of human and mouse orphan nuclear receptor small heterodimer partner promoter by sterol regulatory element binding protein-1. *J Biol Chem* 279: 28122–28131.
26. Foo SY, Heller ER, Wykrzykowska J, Sullivan CJ, Manning-Tobin JJ, et al. (2009) Vascular effects of a low-carbohydrate high-protein diet. *Proc Natl Acad Sci USA* 106: 15418–15423.
27. Petzke KJ, Friedrich M, Metges CC, Klaus S (2005) Long-term dietary high protein intake up-regulates tissue specific gene expression of uncoupling proteins 1 and 2 in rats. *Eur J Nutr* 44: 414–421.
28. Tappy L (1996) Thermic effect of food and sympathetic nervous system activity in humans. *Reprod Nutr Dev* 36: 391–397.
29. Westerterp KR, Wilson SA, Rolland V (1999) Diet induced thermogenesis measured over 24 h in a respiration chamber: effect of diet composition. *Int J Obes Relat Metab Disord* 23: 287–292.
30. Kim JB, Spotts GD, Halvorsen YD, Shih HM, Ellenberger T, et al. (1995) Dual DNA binding specificity of ADD1/SREBP1 controlled by a single amino acid in the basic helix-loop-helix domain. *Mol Cell Biol* 15: 2582–2588.
31. Osborne TF (2000) Sterol regulatory element-binding proteins (SREBPs): key regulators of nutritional homeostasis and insulin action. *J Biol Chem* 275: 32379–32382.
32. Horton JD, Shimomura I, Brown MS, Hammer RE, Goldstein JL, et al. (1998) Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory element-binding protein-2. *J Clin Invest* 101: 2331–2339.
33. Horton JD, Shah NA, Warrington JA, Anderson NN, Park SW, et al. (2003) Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. *Proc Natl Acad Sci U S A* 100: 12027–12032.
34. Bommer GT, MacDougald OA (2011) Regulation of lipid homeostasis by the bifunctional SREBF2-miR33a locus. *Cell Metab* 13: 241–247.
35. Osborne TF, Espenshade PJ (2009) Evolutionary conservation and adaptation in the mechanism that regulates SREBP action: what a long, strange tRIP it's been. *Genes Dev* 23: 2578–2591.
36. Horton JD, Goldstein JL, Brown MS (2002) SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. *J Clin Invest* 109: 1125–1131.
37. Goldstein JL, DeBose-Boyd RA, Brown MS (2006) Protein sensors for membrane sterols. *Cell* 124: 35–46.
38. Radhakrishnan A, Goldstein JL, McDonald JG, Brown MS (2008) Switch-like control of SREBP-2 transport triggered by small changes in ER cholesterol: a delicate balance. *Cell Metab* 8: 512–521.
39. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B (2009) Role of bile acids and bile acid receptors in metabolic regulation. *Physiol Rev* 89: 147–191.
40. Miyake JH, Duong-Polk XT, Taylor JM, Du EZ, Castellani LW, et al. (2002) Transgenic expression of cholesterol-7 α -hydroxylase prevents atherosclerosis in C57BL/6J mice. *Arterioscler Thromb Vasc Biol* 22: 121–126.
41. Bortolotti M, Kreis R, Debard C, Cariou B, Fach D, et al. (2009) High protein intake reduces intrahepatic lipid deposition in humans. *Am J Clin Nutr* 90: 1002–1010.
42. Klaus S (2005) Increasing the protein:carbohydrate ratio in a high-fat diet delays the development of adiposity and improves glucose homeostasis in mice. *J Nutr* 135: 1854–1858.
43. Phillips BE, Hill DS, Atherton PJ (2012) Regulation of muscle protein synthesis in humans. *Curr Opin Clin Nutr Metab Care* 15: 58–63.
44. Linn T, Santosa B, Gronemeyer D, Aygen S, Scholz N, et al. (2000) Effect of long-term dietary protein intake on glucose metabolism in humans. *Diabetologia* 43: 1257–1265.
45. Rossetti L, Rothman DL, DeFronzo RA, Shulman GI (1989) Effect of dietary protein on in vivo insulin action and liver glycogen repletion. *Am J Physiol* 257: E212–E219.
46. Tremblay F, Lavigne C, Jacques H, Marette A (2007) Role of dietary proteins and amino acids in the pathogenesis of insulin resistance. *Annu Rev Nutr* 27: 293–310.
47. Gannon MC, Nuttall FQ (2004) Effect of a high-protein, low-carbohydrate diet on blood glucose control in people with type 2 diabetes. *Diabetes* 53: 2375–2382.
48. Samuel VT, Beddo SA, Iwasaki T, Zhang XM, Chu X, et al. (2009) Fasting hyperglycemia is not associated with increased expression of PEPCK or G6Pc in patients with Type 2 Diabetes. *Proc Natl Acad Sci U S A* 106: 12121–12126.
49. Liu Z, Barrett EJ, Dalkin AC, Zwart AD, Chou JY (1994) Effect of acute diabetes on rat hepatic glucose-6-phosphatase activity and its messenger RNA level. *Biochem Biophys Res Commun* 205: 680–686.
50. Folch J, Lees M, Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipides from animal tissues. *J Biol Chem* 226: 497–509.
51. Van Gelder RN, von Zastrow ME, Yool A, Dement WC, Barchas JD, et al. (1990) Amplified RNA synthesized from limited quantities of heterogeneous cDNA. *Proc Natl Acad Sci U S A* 87: 1663–1667.
52. Mansourian R, Mutch DM, Antille N, Aubert J, Fogel P, et al. (2004) The Global Error Assessment (GEA) model for the selection of differentially expressed genes in microarray data. *Bioinformatics* 20: 2726–2737.